Long-term Efficacy Results of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 (DESTINY PWS) and C602 Open Label Extension (OLE) ...

If you are interested in requesting a one-on-one meeting at the conference, please contact your Piper Sandler representative. About Beyond Air®, Inc. Beyond Air is a commercial stage medical device ...

Revenue: Revenue was $4.7 million for the three months ended September 30, 2024, compared to $6.9 million for the same period in 2023. The decrease was primarily due to lower partnering revenues as a ...

Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew 34% compared to the ...

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per share (basic and ...

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter ...

In October 2024, following suspension of the current SPR720 development plans, Spero underwent a restructuring and reduction in force of approximately 39%, which extended the Company’s cash runway ...

Nouvelle initiative, lancée à l’Université d'Aarhus (Danemark) pour reproduire les avantages du jeûne et/ou de l’exercice pour la santé, à l’aide d’un simple médicament. Initiative qui peut sembler su ...

Près de 8 millions de femmes sont atteintes d'un cancer du sein dans le monde et 33 à 44 % souffrent de douleurs lymphatiques ...

Si le Tai Chi a déjà démontré de nombreux bénéfices pour la santé, cette fois, c’est contre l’insomnie que cette équipe de l'Université de Californie Los Angeles (UCLA Health) documente ses avantages.

LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...